NewAmsterdam Pharma Company N.V. NAMS
19.82 USD -0.90 (-4.37%)
Nov 12, 2026, 11:37 AM EST
19.31 Day range 20.53
17.90 52-week range 42.21
- YTD
- -43.51%
- 1 year
- -48.28%
News
benzinga.com Cantor Fitzgerald Maintains Overweight on NewAmsterdam Pharma Co, Raises Price Target to $61 Cantor Fitzgerald analyst Steve Seedhouse maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight and raises the price target from $52 to $61.
globenewswire.com NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical…
benzinga.com Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $46 Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $48 to $46.- benzinga.com NewAmsterdam Pharma Q3 EPS $(0.14) Beats $(0.51) Estimate, Sales $19.164M Beat $7.340M Estimate NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.51) by 72 percent. This is a 77.05 percent increase over losses of…
benzinga.com RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42 RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.
benzinga.com NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-- The study will evaluate…- benzinga.com NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of
benzinga.com Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
benzinga.com HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $52 price target.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock…- benzinga.com RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50 RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.
- benzinga.com NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 246.67 percent decrease over losses…
benzinga.com NewAmsterdam Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Recommending Marketing Authorization For Ubeslo, Evlarco To Treat Primary Hypercholesterolemia NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of
benzinga.com RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51 RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $47 to $51.
benzinga.com Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday US stocks, including Monster Beverage Corp, rose on Friday. Monster Beverage reported better-than-expected financial results, causing a 12.8% jump in their shares.- benzinga.com NewAmsterdam Pharma Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $3.040M Beat $936.364K Estimate NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 14.89 percent. This is a 17.65 percent decrease over losses of…
benzinga.com Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45 Guggenheim analyst Debjit Chattopadhyay maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $41 to $45.
benzinga.com Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co - benzinga.com Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $48 Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $46 to $48.
benzinga.com Earnings Summary: NewAmsterdam Pharma Co Q4 
benzinga.com Assessing NewAmsterdam Pharma Co: Insights From 5 Financial Analysts 
benzinga.com RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $47 RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $44 to $47.
benzinga.com NewAmsterdam Pharma Issues Update On Obicetrapib Clinical Development Program And Outlines Strategic Priorities For 2026; EMA Approval Decision On Obicetrapib Anticipated In 2H26 -- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 ---- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY ----…- benzinga.com Stifel Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50 Stifel analyst James Condulis maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $44 to $50.
- benzinga.com Goldman Sachs Maintains Neutral on NewAmsterdam Pharma Co, Raises Price Target to $37 Goldman Sachs analyst Asad Haider maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral and raises the price target from $30 to $37.
- benzinga.com RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $44 RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $39 to $44.
- benzinga.com Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $46 Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $40 to $46.
- benzinga.com NewAmsterdam Pharma Q3 EPS $(0.61) Misses $(0.41) Estimate, Sales $348.000K Miss $5.287M Estimate NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.41) by 47.34 percent. This is a 238.89 percent decrease over losses…
- benzinga.com Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)
- benzinga.com HC Wainwright & Co. Assumes NewAmsterdam Pharma Co at Buy, Announces Price Target of $52 HC Wainwright & Co. analyst Joseph Pantginis assumes NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $52.
- benzinga.com Citigroup Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50 Citigroup analyst Geoff Meacham maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $42 to $50.
- benzinga.com Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts
- benzinga.com Wells Fargo Initiates Coverage On NewAmsterdam Pharma Co with Overweight Rating, Announces Price Target of $45 Wells Fargo analyst Yanan Zhu initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight rating and announces Price Target of $45.
- benzinga.com NewAmsterdam Pharma And Piramal Pharma Solutions Invest Multi-Million Dollars In Dedicated Oral Solid Dosage Suite At Sellersville Pennsylvania Facility The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial…
- benzinga.com What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co
- benzinga.com RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $39 RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $38 to $39.
- benzinga.com NewAmsterdam Pharma Q2 EPS $(0.15) Beats $(0.46) Estimate, Sales $19.145M Beat $2.235M Estimate NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.46) by 67.39 percent. This is a 63.41 percent increase over losses of…
- benzinga.com NewAmsterdam's Obicetrapib Reduces Alzheimer's Biomarker p-tau217 In High-Risk ApoE4 Carriers, Supporting CETP Inhibition As Potential Preventive Approach -- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer's disease pathology, in both the full analysis set (p=0.0019) and in…
- benzinga.com 'Biotech Says Its Cholesterol Drug Shows Signs Of Preventing Alzheimer's; NewAmsterdam Pharma Hopes Medicine Born Out Of Big Failures May Have An Unexpected Benefit' - STAT News https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/
- benzinga.com Goldman Sachs Initiates Coverage On NewAmsterdam Pharma Co with Neutral Rating, Announces Price Target of $27 Goldman Sachs analyst Asad Haider initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral rating and announces Price Target of $27.
- benzinga.com Citigroup Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $42 Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $42.
- benzinga.com What Analysts Are Saying About NewAmsterdam Pharma Co Stock
- benzinga.com Needham Reiterates Buy on NewAmsterdam Pharma Co, Maintains $40 Price Target Needham analyst Serge Belanger reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $40 price target.
- benzinga.com Stifel Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $44 Stifel analyst James Condulis initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $44.
benzinga.com Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.- benzinga.com Newamsterdam Pharma Announced Topline Data From Prespecified Alzheimer's Disease Biomarker Analyses In The Phase 3 BROADWAY Trial Of Obicetrapib Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer's disease biomarker in both…
- benzinga.com NewAmsterdam Pharma Scheduled to Participate in June Investor Conferences William Blair 45th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 3, 2025. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 3:20 p.m. CT on…
- benzinga.com Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $40 Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $42 to $40.
- benzinga.com NewAmsterdam Pharma Q1 EPS $(0.34) Beats $(0.48) Estimate, Sales $2.98M Beat $1.58M Estimate NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.48) by 29.17 percent. The company reported quarterly sales of $2.98…
- benzinga.com Newamsterdam Pharma Presents Addl Data From BROADWAY And TANDEM Pivotal Phase 3 Studies As Late-breaking Oral Presentations At EAS 2025 And Publishes In Leading Medical Journals – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) –– Phase 3 data showed that…